Anbio Biotechnology Class A Ordinary Shares (NNNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) has a cash flow conversion efficiency ratio of 0.093x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.60 Million) by net assets ($17.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NNNN market cap for the company's overall valuation and market capitalisation.
Anbio Biotechnology Class A Ordinary Shares - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Anbio Biotechnology Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anbio Biotechnology Class A Ordinary Shares ranked by their cash flow conversion efficiency. Explore Anbio Biotechnology Class A Ordinary Sha (NNNN) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
P.C.B Tec
TA:PCBT
|
0.032x |
|
Grupa Azoty Zaklady Chemiczne Police SA
WAR:PCE
|
0.539x |
|
Gersan Elektrik Ticaret ve Sanayi AS
IS:GEREL
|
-0.369x |
|
Natac Natural Ingredients, S.A.
MC:NAT
|
0.221x |
|
888 Holdings plc
F:C8V
|
-0.007x |
|
SILENCE THERAP. SP.ADR/1
F:XRP2
|
-0.277x |
|
Roman DBDR Acquisition Corp. II Ordinary shares
NASDAQ:DRDB
|
-0.001x |
|
RoadMain T Co Ltd
SHG:603860
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Anbio Biotechnology Class A Ordinary Shares (2021–2025)
The table below shows the annual cash flow conversion efficiency of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2025. View current stock price of Anbio Biotechnology Class A Ordinary Sha for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.16 Million | $-6.74 Million | -0.223x | -284.68% |
| 2024-12-31 | $17.19 Million | $2.08 Million | 0.121x | +99.61% |
| 2023-12-31 | $14.82 Million | $898.37K | 0.061x | -82.90% |
| 2022-12-31 | $12.55 Million | $4.45 Million | 0.355x | -78.50% |
| 2021-12-31 | $2.54 Million | $4.18 Million | 1.649x | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/… Read more